Skip to main content
Top
Published in: Journal of Gastroenterology 1/2016

01-01-2016 | Original Article—Liver, Pancreas, and Biliary Tract

Comparison of gadoxetic acid-enhanced magnetic resonance imaging and contrast-enhanced computed tomography with histopathological examinations for the identification of hepatocellular carcinoma: a multicenter phase III study

Authors: Masakatsu Tsurusaki, Keitaro Sofue, Hiroyoshi Isoda, Masahiro Okada, Kazuhiro Kitajima, Takamichi Murakami

Published in: Journal of Gastroenterology | Issue 1/2016

Login to get access

Abstract

Background

Gadoxetic acid-enhanced magnetic resonance imaging (MRI) has an important role in preoperative evaluation of hepatocellular carcinoma (HCC). However, no studies have prospectively performed intraindividual comparison of gadoxetic acid-enhanced 3T MRI and multidetector-row computed tomography (MDCT) with histopathological examination for the detection of HCCs. We prospectively compared the efficacies of gadoxetic acid-enhanced MRI and multiphasic contrast-enhanced MDCT with that of histopathological examination, used as a reference standard, for the detection of HCC in surgical candidates.

Methods

The study was approved by the institutional review boards at each of four centers. Patients scheduled to undergo multiphasic CT, gadoxetic acid-enhanced MRI, and liver surgery were prospectively included in this study. The diagnostic abilities of MRI and CT were evaluated and compared on the basis of sensitivity and positive predictive value for detection of and differentiation between HCCs and benign lesions.

Results

Fifty-four patients with 83 histopathologically confirmed HCCs were included in the study. Combined interpretation of the dynamic and hepatobiliary phases of gadoxetic acid-enhanced MRI showed statistically higher sensitivity for lesion detection (83 %) than did interpretation of multiphasic MDCT images (70 %; p < 0.001). The mean area under each alternative free-response receiver operating characteristics curve was significantly higher for MR images (0.927) than for CT images (0.864, p < 0.01).

Conclusions

The sensitivity for preoperative detection of HCCs was higher for gadoxetic acid-enhanced MRI than for multiphasic MDCT imaging.
Literature
1.
go back to reference Kim SH, Choi D, Kim SH, et al. Ferucarbotran-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR. 2005;184:1069–76.PubMedCrossRef Kim SH, Choi D, Kim SH, et al. Ferucarbotran-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR. 2005;184:1069–76.PubMedCrossRef
2.
go back to reference Kopp AF, Heuschmid M, Claussen CD. Multidetector helical CT of the liver for tumor detection and characterization. Eur Radiol. 2002;12:745–52.PubMedCrossRef Kopp AF, Heuschmid M, Claussen CD. Multidetector helical CT of the liver for tumor detection and characterization. Eur Radiol. 2002;12:745–52.PubMedCrossRef
3.
go back to reference Iannaccone R, Laghi A, Catalano C, et al. Hepatocellular carcinoma: role of unenhanced and delayed phase multi-detector row helical CT in patients with cirrhosis. Radiology. 2005;234:460–7.PubMedCrossRef Iannaccone R, Laghi A, Catalano C, et al. Hepatocellular carcinoma: role of unenhanced and delayed phase multi-detector row helical CT in patients with cirrhosis. Radiology. 2005;234:460–7.PubMedCrossRef
4.
go back to reference Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology. 2008;47:97–104.PubMedCrossRef Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology. 2008;47:97–104.PubMedCrossRef
5.
go back to reference Peterson MS, Baron RL, Marsh JW Jr, Oliver JH 3rd, Confer SR, Hunt LE. Pretransplantation surveillance for possible hepatocellular carcinoma in patients with cirrhosis: epidemiology and CT-based tumor detection rate in 430 cases with surgical pathologic correlation. Radiology. 2000;217:743–9.PubMedCrossRef Peterson MS, Baron RL, Marsh JW Jr, Oliver JH 3rd, Confer SR, Hunt LE. Pretransplantation surveillance for possible hepatocellular carcinoma in patients with cirrhosis: epidemiology and CT-based tumor detection rate in 430 cases with surgical pathologic correlation. Radiology. 2000;217:743–9.PubMedCrossRef
6.
go back to reference Lim JH, Kim CK, Lee WJ, et al. Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic livers: accuracy of helical CT in transplant patients. AJR. 2000;175:693–8.PubMedCrossRef Lim JH, Kim CK, Lee WJ, et al. Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic livers: accuracy of helical CT in transplant patients. AJR. 2000;175:693–8.PubMedCrossRef
7.
go back to reference Krinsky GA, Lee VS, Theise ND, et al. Hepatocellular carcinoma and dysplastic nodules in patients with cirrhosis: prospective diagnosis with MR imaging and explantation correlation. Radiology. 2001;219:445–54.PubMedCrossRef Krinsky GA, Lee VS, Theise ND, et al. Hepatocellular carcinoma and dysplastic nodules in patients with cirrhosis: prospective diagnosis with MR imaging and explantation correlation. Radiology. 2001;219:445–54.PubMedCrossRef
8.
go back to reference Krinsky GA, Lee VS, Theise ND, et al. Transplantation for hepatocellular carcinoma and cirrhosis: sensitivity of magnetic resonance imaging. Liver Transpl. 2002;8:1156–64.PubMedCrossRef Krinsky GA, Lee VS, Theise ND, et al. Transplantation for hepatocellular carcinoma and cirrhosis: sensitivity of magnetic resonance imaging. Liver Transpl. 2002;8:1156–64.PubMedCrossRef
9.
go back to reference Rode A, Bancel B, Douek P, et al. Small nodule detection in cirrhotic livers: evaluation with US, spiral CT, and MRI and correlation with pathologic examination of explanted liver. J Comput Assist Tomogr. 2001;25:327–36.PubMedCrossRef Rode A, Bancel B, Douek P, et al. Small nodule detection in cirrhotic livers: evaluation with US, spiral CT, and MRI and correlation with pathologic examination of explanted liver. J Comput Assist Tomogr. 2001;25:327–36.PubMedCrossRef
10.
go back to reference Petersein J, Spinazzi A, Giovagnoni A, et al. Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging—a multicenter phase III clinical study. Radiology. 2000;215:727–36.PubMedCrossRef Petersein J, Spinazzi A, Giovagnoni A, et al. Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging—a multicenter phase III clinical study. Radiology. 2000;215:727–36.PubMedCrossRef
11.
go back to reference Kim JI, Lee JM, Choi JY, et al. The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver. Invest Radiol. 2008;43:202–10.PubMedCrossRef Kim JI, Lee JM, Choi JY, et al. The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver. Invest Radiol. 2008;43:202–10.PubMedCrossRef
12.
go back to reference Kim YK, Kim CS, Chung GH, et al. Comparison of gadobenate dimeglumine-enhanced dynamic MRI and 16-MDCT for the detection of hepatocellular carcinoma. AJR. 2006;186:149–57.PubMedCrossRef Kim YK, Kim CS, Chung GH, et al. Comparison of gadobenate dimeglumine-enhanced dynamic MRI and 16-MDCT for the detection of hepatocellular carcinoma. AJR. 2006;186:149–57.PubMedCrossRef
13.
go back to reference Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD Initiative. Radiology. 2003;226:24–8.PubMedCrossRef Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD Initiative. Radiology. 2003;226:24–8.PubMedCrossRef
14.
go back to reference Jang HJ, Lim JH, Lee SJ, Park CK, Park HS. DoYS. Hepatocellular carcinoma: are combined CT during arterial portography and CT hepatic arteriography in addition to triple-phase helical CT all necessary for preoperative evaluation? Radiology. 2000;215:373–80.PubMedCrossRef Jang HJ, Lim JH, Lee SJ, Park CK, Park HS. DoYS. Hepatocellular carcinoma: are combined CT during arterial portography and CT hepatic arteriography in addition to triple-phase helical CT all necessary for preoperative evaluation? Radiology. 2000;215:373–80.PubMedCrossRef
15.
go back to reference Kang BK, Lim JH, Kim SH, et al. Preoperative depiction of hepatocellular carcinoma: ferumoxides- enhanced MR imaging versus triple-phase helical CT. Radiology. 2003;226:79–85.PubMedCrossRef Kang BK, Lim JH, Kim SH, et al. Preoperative depiction of hepatocellular carcinoma: ferumoxides- enhanced MR imaging versus triple-phase helical CT. Radiology. 2003;226:79–85.PubMedCrossRef
16.
go back to reference Huppertz A, Haraida S, Kraus A, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT—initial observations. Radiology. 2005;234:468–78.PubMedCrossRef Huppertz A, Haraida S, Kraus A, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT—initial observations. Radiology. 2005;234:468–78.PubMedCrossRef
17.
go back to reference Kim SH, Kim SH, Lee J, et al. Gadoxetic acid-enhanced MRI versus triplephase MDCT for the preoperative detection of hepatocellular carcinoma. AJR. 2009;192:1675–81.PubMedCrossRef Kim SH, Kim SH, Lee J, et al. Gadoxetic acid-enhanced MRI versus triplephase MDCT for the preoperative detection of hepatocellular carcinoma. AJR. 2009;192:1675–81.PubMedCrossRef
18.
go back to reference Murakami T, Kim T, Takamura M, et al. Hypervascular hepatocellular carcinoma: detection with double arterial phase multi-detector row helical CT. Radiology. 2001;218:763–7.PubMedCrossRef Murakami T, Kim T, Takamura M, et al. Hypervascular hepatocellular carcinoma: detection with double arterial phase multi-detector row helical CT. Radiology. 2001;218:763–7.PubMedCrossRef
19.
go back to reference Kwak HS, Lee JM, Kim CS. Preoperative detection of hepatocellular carcinoma: comparison of combined contrast-enhanced MR imaging and combined CT during arterial portography and CT hepatic arteriography. Eur Radiol. 2004;14:447–57.PubMedCrossRef Kwak HS, Lee JM, Kim CS. Preoperative detection of hepatocellular carcinoma: comparison of combined contrast-enhanced MR imaging and combined CT during arterial portography and CT hepatic arteriography. Eur Radiol. 2004;14:447–57.PubMedCrossRef
20.
go back to reference Kim YK, Kim CS, Han YM, et al. Detection of hepatocellular carcinoma: gadoxetic acid-enhanced 3-dimensional magnetic resonance imaging versus multi-detector row computed tomography. J Comput Assist Tomogr. 2009;33:844–50.PubMedCrossRef Kim YK, Kim CS, Han YM, et al. Detection of hepatocellular carcinoma: gadoxetic acid-enhanced 3-dimensional magnetic resonance imaging versus multi-detector row computed tomography. J Comput Assist Tomogr. 2009;33:844–50.PubMedCrossRef
21.
go back to reference Hwang J, Kim SH, Lee MW, Lee JY. Small (≤2 cm) hepatocellular carcinoma in patients with chronic liver disease: comparison of gadoxetic acid-enhanced 3.0 T MRI and multiphasic 64-multirow detector CT. Br J Radiol. 2012;85:e314–22.PubMedPubMedCentralCrossRef Hwang J, Kim SH, Lee MW, Lee JY. Small (≤2 cm) hepatocellular carcinoma in patients with chronic liver disease: comparison of gadoxetic acid-enhanced 3.0 T MRI and multiphasic 64-multirow detector CT. Br J Radiol. 2012;85:e314–22.PubMedPubMedCentralCrossRef
22.
go back to reference Onishi H, Kim T, Imai Y, et al. Hypervascular hepatocellular carcinomas: detection with gadoxetate disodium-enhanced MR imaging and multiphasic multidetector CT. Eur Radiol. 2012;22:845–54.PubMedCrossRef Onishi H, Kim T, Imai Y, et al. Hypervascular hepatocellular carcinomas: detection with gadoxetate disodium-enhanced MR imaging and multiphasic multidetector CT. Eur Radiol. 2012;22:845–54.PubMedCrossRef
23.
go back to reference Merkle EM, Dale BM, Paulson EK. Abdominal MR Imaging at 3.0 T. Magn Reson Imaging Clin N Am. 2006;14:17–26.PubMedCrossRef Merkle EM, Dale BM, Paulson EK. Abdominal MR Imaging at 3.0 T. Magn Reson Imaging Clin N Am. 2006;14:17–26.PubMedCrossRef
24.
go back to reference Ramalho M, Altun E, Heredia V, Zapparoli M, Semelka R. Liver MR imaging: 1.5 T versus 3 T. Magn Reson Imaging Clin N Am. 2007;15:321–47.PubMedCrossRef Ramalho M, Altun E, Heredia V, Zapparoli M, Semelka R. Liver MR imaging: 1.5 T versus 3 T. Magn Reson Imaging Clin N Am. 2007;15:321–47.PubMedCrossRef
25.
go back to reference Hussain SM, Wielopolski PA, Martin DR. Abdominal magnetic resonance imaging at 3.0 T: problem or a promise for the future? Top Magn Reson Imaging. 2005;16:325–35.PubMedCrossRef Hussain SM, Wielopolski PA, Martin DR. Abdominal magnetic resonance imaging at 3.0 T: problem or a promise for the future? Top Magn Reson Imaging. 2005;16:325–35.PubMedCrossRef
26.
go back to reference von Falkenhausen MM, Lutterbey G, Morakkabati-Spitz N, et al. High-field-strength MR imaging of the liver at 3.0 T: intraindividual comparative study with MR imaging at 1.5 T. Radiology. 2006;241:156–66.CrossRef von Falkenhausen MM, Lutterbey G, Morakkabati-Spitz N, et al. High-field-strength MR imaging of the liver at 3.0 T: intraindividual comparative study with MR imaging at 1.5 T. Radiology. 2006;241:156–66.CrossRef
27.
go back to reference Tsurusaki M, Semelka RC, Zapparoli M, Elias J Jr, Altun E, Pamuklar E, Sugimura K. Quantitative and qualitative comparison of 3.0 T and 1.5 T MR imaging of the liver in patients with diffuse parenchymal liver disease. Eur J Radiol. 2009;72:314–20.PubMedCrossRef Tsurusaki M, Semelka RC, Zapparoli M, Elias J Jr, Altun E, Pamuklar E, Sugimura K. Quantitative and qualitative comparison of 3.0 T and 1.5 T MR imaging of the liver in patients with diffuse parenchymal liver disease. Eur J Radiol. 2009;72:314–20.PubMedCrossRef
28.
go back to reference Ramalho M, Herédia V, Tsurusaki M, Altun E, Semelka RC. Quantitative and qualitative comparison of 1.5 and 3.0 Tesla MRI in patients with chronic liver diseases. J Magn Reson Imaging. 2009;29:869–79.PubMedCrossRef Ramalho M, Herédia V, Tsurusaki M, Altun E, Semelka RC. Quantitative and qualitative comparison of 1.5 and 3.0 Tesla MRI in patients with chronic liver diseases. J Magn Reson Imaging. 2009;29:869–79.PubMedCrossRef
29.
go back to reference Zapparoli M, Semelka RC, Altun E, Tsurusaki M, Pamuklar E, Dale BM, Gasparetto EL, Elias J Jr. 3.0-T MRI evaluation of patients with chronic liver diseases: initial observations. Magn Reson Imaging. 2008;26:650–60.PubMedCrossRef Zapparoli M, Semelka RC, Altun E, Tsurusaki M, Pamuklar E, Dale BM, Gasparetto EL, Elias J Jr. 3.0-T MRI evaluation of patients with chronic liver diseases: initial observations. Magn Reson Imaging. 2008;26:650–60.PubMedCrossRef
30.
go back to reference Chang KJ, Kamel IR, Macura KJ, Bluemke DA. 3.0-T MR imaging of the abdomen: comparison with 1.5 T. Radiographics. 2008;28:1983–98.PubMedCrossRef Chang KJ, Kamel IR, Macura KJ, Bluemke DA. 3.0-T MR imaging of the abdomen: comparison with 1.5 T. Radiographics. 2008;28:1983–98.PubMedCrossRef
Metadata
Title
Comparison of gadoxetic acid-enhanced magnetic resonance imaging and contrast-enhanced computed tomography with histopathological examinations for the identification of hepatocellular carcinoma: a multicenter phase III study
Authors
Masakatsu Tsurusaki
Keitaro Sofue
Hiroyoshi Isoda
Masahiro Okada
Kazuhiro Kitajima
Takamichi Murakami
Publication date
01-01-2016
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 1/2016
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-015-1097-5

Other articles of this Issue 1/2016

Journal of Gastroenterology 1/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.